Streetbeat News

ESPR

Esperion Therapeutics, Inc.

https://www.esperion.com

Industry

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Open

2.03

Mkt cap

414M

Volume

12M

High

2.14

P/E Ratio

-2.48

52-wk high

3.40

Low

1.87

Div yield

N/A

52-wk low

0.87

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $22 price target.

Portfolio Pulse from richadhand@benzinga.com

August 28, 2023 | 10:41 am

Esperion presented results from two CLEAR Outcomes Study late-breakers at the European Society of Cardiology Congress 2023. The cardiovascular event analysis showed that Bempedoic Acid resulted in a 20% and 17% risk reduction in MACE-4 and MACE-3 respectively. The analysis was conducted on patients with diabetes.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 8:37 am

Esperion Therapeutics (NASDAQ:ESPR) has announced two oral presentations at the 2023 ESC Congress in Amsterdam. The presentations, part of the Late-Breaking Science Session, will focus on clinical trial updates on prevention and lipid lowering.

Portfolio Pulse from Happy Mohamed

August 11, 2023 | 12:08 pm

Esperion Therapeutics (NASDAQ:ESPR) has received five bullish analyst ratings in the last quarter, with an average 12-month price target of $13.4, a significant increase from the previous average of $7.75. No bearish or neutral ratings were observed.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 11:55 am

Needham analyst Serge Belanger has maintained a 'Buy' rating on Esperion Therapeutics (NASDAQ:ESPR) but lowered the price target from $10 to $9.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:41 am

Esperion Therapeutics reported better-than-expected Q2 financial results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:44 am

Esperion Therapeutics, Inc. (ESPR) reported a 26% year-over-year growth in Q2 retail prescription equivalents and a 28% quarter-over-quarter growth in Q2 new to brand prescriptions.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 10:08 am

Esperion Therapeutics reported Q2 earnings per share (EPS) of $(0.46), beating the analyst consensus estimate of $(0.63) by 26.98%. This is a 56.19% increase over losses from the same period last year. The company also reported quarterly sales of $25.79 million, beating the analyst consensus estimate of $25.50 million by 1.12%, a 36.86% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 10:05 am

Esperion (NASDAQ:ESPR) will present additional data from the CLEAR Outcomes study on cardiovascular disease (CVD) prevention at the 2023 American Society for Preventive Cardiology Congress. The presentation will focus on the use of ezetimibe among participants in the trial.

Portfolio Pulse from Happy Mohamed

July 07, 2023 | 12:03 pm

Esperion has submitted an application to the European Medicines Agency for an expanded indication for its NILEMDO and NUSTENDI tablets. This could potentially open up new markets for the company's products.

Portfolio Pulse from Bill Haddad

June 28, 2023 | 12:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.